D.E. Shaw & Co’s Citius Pharmaceuticals CTXR Stock Holding History

D.E. Shaw & Co’s Portfolio CTXR Stock Details CTXR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-2,166	Closed	-$188K	–	5009
2021 Q2	$188K	Buy	+2,166	New	+$130K	﹤0.01%	4458

Other funds holding CTXR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

D.E. Shaw & Co's CTXR Position: Q3 2021 in Review

D.E. Shaw & Co sold out of Citius Pharmaceuticals (CTXR) in Q3 2021, closing a stake of 2,166 shares — an estimated $188K sold.

D.E. Shaw & Co first reported a position in CTXR in Q2 2021 and held it in 1 quarter. The position peaked at $188K in Q2 2021. 71 funds tracked by Wall St. Rank hold CTXR as of Q3 2021.

D.E. Shaw & Co reported no remaining Citius Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
D.E. Shaw & Co sold 2,166 Citius Pharmaceuticals shares in Q3 2021, an estimated $188K.
D.E. Shaw & Co first reported a position in Citius Pharmaceuticals in Q2 2021 and held it in 1 quarter.
D.E. Shaw & Co's Citius Pharmaceuticals position peaked at $188K in Q2 2021.
71 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q3 2021.

Based on D.E. Shaw & Co's 13F filing for Q3 2021, filed 15 Nov 2021.